Lotte Biologics announced on the 13th that it has signed a memorandum of understanding (MOU) for collaboration in the contract development and manufacturing organization (CDMO) business with Asimov, based in Boston, Massachusetts.
With this agreement, Lotte Biologics plans to provide comprehensive services from cell line development to GMP (Good Manufacturing Practice) production utilizing Asimov's next-generation cell line development platform technology.
Previously, Lotte Biologics confirmed that it could successfully scale up and mass-produce through the application test of Asimov's proprietary cell line development platform, the CHO Edge system, at the Syracuse Bio Campus.
Asimov's CHO Edge system is a cell line development platform based on synthetic biology that accelerates the production of antibodies and protein therapeutics through gene design and optimization of CHO (Chinese Hamster Ovary) cells. It particularly supports the rapid development of customized cell lines with high productivity and uniformity by applying automation of the work process and AI-based analysis. According to the company, the combination of the CHO Edge system with Lotte Biologics' GMP manufacturing capabilities has enabled a seamless connection from cell line development to commercial production.
James Park, CEO of Lotte Biologics, said, "I hope this agreement will serve as an opportunity to maximize the strengths of both companies" and noted, "We will continue to strive to provide differentiated services to our customers through the synergy of Asimov's technological capabilities and Lotte Biologics' production capacity, while contributing to the development of the biotechnology industry and ultimately improving the quality of life for patients."